替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床分析

目的：比较替吉奥联合奥沙利铂一线治疗晚期结直肠癌的临床疗效及安全性。方法回顾性分析48例晚期结直肠癌患者。对照组20例，采用奥沙利铂（85 mg／m2加入5％葡萄糖注射液500 mL静脉滴注，25 d为1个周期）联合卡培他滨[2500 mg／（m2·d），口服，2次／d，21 d 为1个周期]治疗；观察组28例，采用替吉奥（20 mg／d，25 d为1个周期）联合奥沙利铂（85 mg／m2加入5％葡萄糖注射液500 mL静脉滴注，20 d为1个周期）一线治疗。比较治疗前与治疗后25 d的临床疗效及安全性。结果治疗后25 d，观察组临床有效率及疾病控制率均高于对照组（48．8％、66．6％ vs 33．6％、50．3％，均P＜0．05）。在安全性方面，观察组血小板降低发生率低于对照组，差异具有统计学意义（35．5％ vs 62．3％，P＜0．05）；贫血、呼吸道反应及肝功能受损发生率与对照组比较差异均无统计学意义（45．5％、46．8％、43．5％ vs 47．2％、47．4％、45．8％，均P＞0．05）。结论与奥沙利铂联合卡培他滨比较，替吉奥联合奥沙利铂一线治疗晚期结直肠癌临床疗效和安全性更优。

Clinical analysis of S-1 combined with oxaliplatin as first-line treatment for advanced colorectal cancer

Objective To examine the effect and security of tegafur,gimeracil and oteracil potassium (S-1 )com-bined with oxaliplatin as first-line therapy for advanced colorectal cancer.Methods Forty-eight cases of advanced colorec-tal cancer patients were retrospectively analyzed.The control group included 20 cases,and was treated by oxaliplatin (85 mg/m2 ,in 500 mL 5% glucose,ivgtt,for 25 d as a cycle)combined with capecitabine (2 500 mg/(m2 ·d),bid,for 21 d as a cycle).The study group included 28 cases,and was treated by S-1 (20 mg/d for 25 d as a cycle)combined with oxaliplatin (85 mg/m2 ,in 500 mL 5%glucose,ivgtt,for 20 d as a cycle)as the first-line treatment.The clinical efficacy and safety of the patients were compared before and after the treatment.Results Twenty-five days after the treatment, both the clinical effective rate and the disease control rate were higher in the study group than the control group (48.8%vs 33.6%,66.6%vs 50.3%,respectively,P<0.05).In the aspects of safety,the incidence of thrombocytopenia was low-er in the study group than in the control group (35.5%vs 62.3%,P<0.05),whereas the incidences of anemia,respira-tory tract reaction and liver function damage were all comparable between the two groups (study group:45.5%,46.8%, 43.5%;control group:47.2%,47.4%,45.8%;all P>0.05).Conclusion Compared with oxaliplatin and capecit-abine combined therapy,S-1 and oxaliplatin combined therapy has higher clinical efficacy and safety in the first-line treat-ment of advanced colorectal cancer.